Loading
CCNE1 (G1/S-specific cyclin-E1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.
Essential for the control of the cell cycle at the G1/S (start) transition.
CIViC holds 16 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib, Dinaciclib, CDK Inhibitor SNS-032 and Camonsertib and others. Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes affected pathway 0.57, literature 0.99, genetic association 0.57, somatic mutation 0.96, animal model 0.64). In OnCo, 1 product record names it (AVZO-021).
In plain words · CCNE1 (G1/S-specific cyclin-E1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.
CCNE1 (G1/S-specific cyclin-E1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.
Essential for the control of the cell cycle at the G1/S (start) transition. Location: Nucleus (UniProt).
No product in this corpus aims at CCNE1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Tumour-associated overexpression: HPA finds the RNA tissue enhanced in normal bone marrow, placenta, so the tumour and the normal tissue it comes from share the target and the medicine relies on the difference in level. HPA CCNE1: RNA tissue enhanced (bone marrow 34 nTPM, placenta 29 nTPM); high antibody staining in 4 normal tissues; highest cancer staining carcinoid (1 of 4 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Biliary tract cancer (all types), Gastric & gastro-oesophageal junction cancer, Breast cancer (all types), Ovarian cancer, Endometrial cancer, Colorectal cancer, Bladder & urothelial cancer and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas CCNE1 tissue; Human Protein Atlas CCNE1 pathology; Open Targets ENSG00000105173 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Lew D.J. et al, Cell, 1991, "Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast". Source.
Sources: HGNC HGNC:1589 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P24864 (protein name, function text, keywords and locations (REST API)); CIViC gene CCNE1 (16 evidence items, 0 assertions, 3 variants; diseases: Ovarian Cancer, Breast Cancer, Gastric Adenosquamous Carcinoma, Ovarian Carcinoma, Stomach Cancer and 4 more (GraphQL API, CC0)); Open Targets ENSG00000105173 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.58, gastric cancer 0.51, urinary bladder cancer 0.52, skin cancer 0.50, breast cancer 0.50 (GraphQL API, CC0))
Essential for the control of the cell cycle at the G1/S (start) transition. Location: Nucleus (UniProt). Locus 19q12 (HGNC).
RNA: tissue enhanced (bone marrow 34 nTPM, placenta 29 nTPM), detected in many normal tissues.
Medium: Bone marrow, Bronchus, Nasopharynx, Ovary, Urinary bladder.
Medium only: breast cancer, colorectal cancer, head and neck cancer, lung cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Gallbladder cancer | 9% | Amplification | Amplification in 22 of 244 samples, 9.0%, in cBioPortal gbc_mskcc_2022. | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"CCNE1" OR ABSTRACT:"CCNE1" OR TITLE:"cyclin E1" OR ABSTRACT:"cyclin E1" OR TITLE:"G1/S-specific cyclin-E1" OR ABSTRACT:"G1/S-specific cyclin-E1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCNE1, not a curated reading list.
Shares Synthetic lethality: paired dependencies, Endometrial cancer, Skin cancer (all types), Gastric & gastro-oesophageal junction cancer.
Shares AVZO-021, Endometrial cancer, Ovarian cancer.
Shares Synthetic lethality: paired dependencies, Open Targets Platform.
Shares Synthetic lethality: paired dependencies, Bladder & urothelial cancer, Gallbladder cancer, CIViC.
Shares Synthetic lethality: paired dependencies, Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
Shares Synthetic lethality: paired dependencies, Endometrial cancer, Ovarian cancer.
Shares Synthetic lethality: paired dependencies, Gallbladder cancer, Ovarian cancer.